Danish global leader in diabetes and obesity care — maker of Ozempic, Wegovy, NovoRapid and Tresiba. Commercialises its full portfolio in Portugal through a Lisbon-area subsidiary.
Novo Nordisk has operated in Portugal for decades through its local affiliate Novo Nordisk Comércio Produtos Farmacêuticos Lda, headquartered in Paço de Arcos in the Oeiras municipality of the Lisbon metropolitan area. The Portuguese organisation is responsible for regulatory affairs, market access, medical affairs and the commercialisation of Novo Nordisk's diabetes, obesity, haemophilia and growth-disorder portfolios in collaboration with INFARMED (Portugal's medicines regulator) and the SNS.
The Portugal affiliate sits within Novo Nordisk's Region Europe organisation. Its priority products in 2024-2026 mirror the global picture: GLP-1 receptor agonists Ozempic and Wegovy — the latter approved for chronic weight management — alongside the long-established insulin franchise (Tresiba, NovoRapid, Levemir).
Novo Nordisk is now Europe's most valuable listed company by market capitalisation, propelled by demand for its GLP-1 obesity treatments. That makes its Portuguese affiliate one of the most strategically important Nordic-owned healthcare operations in the country, and a benchmark for how Nordic life-sciences companies bring innovative therapies into the Portuguese system.
For the Portugal ↔ Scandinavia corridor, Novo Nordisk represents the long-cycle Nordic pharma presence: a multidecade Portuguese affiliate quietly running one of the most consequential drug portfolios in the country.
Fractio helps Nordic companies enter the Portuguese market — from market sizing to first sales, hiring, and legal setup.
Talk to Fractio →